MedTrace Logo

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

NCT00697632 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 180

Last updated 2019-02-12

No results posted yet for this study

Summary

In this study, MGCD265, a new anticancer drug under investigation, is given daily to patients with advanced malignancies to study its safety profile.

Conditions

Interventions

DRUG

MGCD265

Oral daily administration without interruption

Sponsors & Collaborators

  • Mirati Therapeutics Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2018-09-30
Completion
2019-01-31

Countries

  • United States
  • Canada
  • South Korea

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00697632 on ClinicalTrials.gov